We recently published a list of 10 Stocks Insiders Are Selling In March. In this article, we are going to take a look at ...

Enhanced assay granted approval by New York State’s Clinical Lab Evaluation Program (CLEP) for patients with DLBCL clonoSEQ is the only DLBCL MRD ...

“The PRECISE-HL trial represents a significant milestone in our pursuit of using MRD to personalise therapy for patients. This study complements the SHORTEN-ctDNA trial in diffuse large B-cell ...

Recently, the company announced it has launched an upgraded version of its clonoSEQ assay for measurable residual disease (MRD) detection in diffuse large B-cell lymphoma (DLBCL) using circulating ...

for patients with DLBCL clonoSEQ is the only DLBCL MRD assay available for clinical use and covered by Medicare SEATTLE, March 11, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ...

Adaptive Biotechnologies (ADPT) has launched an upgraded version of its clonoSEQ assay for measurable residual disease detection in diffuse ...

clonoSEQ is the only DLBCL MRD assay available for clinical use and covered by Medicare SEATTLE, March 11, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a ...

SEATTLE, March 11, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune ...